CRISPR-Cas9 hits its target in amyloidosis.
Nature medicine, 28(12): 2438 PMID 36224265 DOI 10.1038/d41591-022-00101-4
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.